How can we better identify early HIV infections?

Current Opinion in HIV and AIDS

Volumn 10, Issue 1, 2015, Pages 61-68

  Rosenberg, Nora E ^a,b   Pilcher, Christopher D ^c   Busch, Michael P ^c,d   Cohen, Myron S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

Acute HIV infection; Early HIV infection; Fourth generation; Multiassay algorithm; Point of care

Indexed keywords

ANTIGEN P24; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS RNA; BIOLOGICAL MARKER;

AFRICA SOUTH OF THE SAHARA; ALGORITHM; CLINICAL FEATURE; DIARRHEA; ENZYME IMMUNOASSAY; FEVER; HIGH RESOLUTION MELTING ANALYSIS; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; RASH; REVIEW; VIREMIA; VIRUS LOAD; EARLY DIAGNOSIS; HEALTH CARE DELIVERY; HIV INFECTIONS; METABOLISM; POINT OF CARE SYSTEM;

ALGORITHMS; BIOMARKERS; DELIVERY OF HEALTH CARE; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; POINT-OF-CARE SYSTEMS;

EID: 84918550195     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000121     Document Type: Review

References (106)

1. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
2. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333-1339.
3. Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013; 10:56.
4. Bebell LM, Pilcher CD, Dorsey G, et al. Acute HIV-1 infection ishighly prevalent in Ugandan adults with suspected malaria. AIDS 2010; 24:1945-1952.
5. Sanders EJ, Mugo P, Prins HA, et al. Acute HIV-1 infection is as common as malaria in young febrile adults seeking care in coastal Kenya. AIDS 2014; 28:1357-1363.
6. Serna-Bolea C, Munoz J, Almeida JM, et al. High prevalence of symptomatic acute HIV infection in an outpatient ward in southern Mozambique: identification and follow-up. AIDS 2010; 24:603-608.
7. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954.
8. Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr 2013; 63 (Suppl 2):S187-S199.
9. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873.
10. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 2008; 3:356-361.
11. Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013; 207:1703-1712.
12. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23.
13. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012; 205:87-96.
14. Spartac Trial Investigators, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368:207-217.
15. Grijsen ML, Steingrover R, Wit FW, et al. Notreatment versus 24or60weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012; 9:e1001196.
16. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218-230.
17. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-733.
18. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154-163.
19. Spudich SS. CROI 2014: neurologic complications of HIV infection. Top Antivir Med 2014; 22:594-601.
20. Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:390-409.
21. Eaton JW, Hallett TB, Garnett GP. Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav 2011; 15:687-692.
22. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
23. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256-268.
24. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav 2008; 12:677-684.
25. Rosenberg NE, Pettifor AE, Bruyn GD, et al. HIV Testing and Counseling Leads to Immediate Consistent Condom Use Among South African Stable HIV-Discordant Couples. J Acquir Immune Defic Syndr 2013; 62: 226-233.
26. Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research. Am J Public Health 1999; 89:1397-1405.
27. Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav 2009; 13:1054-1060.
28. Laeyendecker O, Kulich M, Donnell D, et al. Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One 2013; 8:e78818.
29. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-39.
30. Prins HA, Mugo P, Wahome E, et al. Diagnosing acute and prevalent HIV-1 infection in young African adults seeking care for fever: a systematic review and audit of current practice. Int Health 2014; 6:82-92.
31. Powers KA, Cohen MS. Acute HIV-1 infection in sub-Saharan Africa: a common occurrence overlooked. AIDS 2014; 28:1365-1367.
32. Powers KA, Miller WC, Pilcher CD, et al. Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS 2007; 21:2237-2242.
33. Wahome E, Fegan G, Okuku HS, et al. Evaluation of anempiric risk screening score to identify acute and early HIV-1 infection among MSM in Coastal Kenya. AIDS 2013; 27:2163-2166.
34. Mlisana K, Sobieszczyk M, Werner L, et al. Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing. PLoS One 2013; 8:e62928.
35. Facente SN, Pilcher CD, Hartogensis WE, et al. Performance of risk-based criteria for targeting acute HIV screening in San Francisco. PLoS One 2011; 6:e21813.
36. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-1883.
37. Klausner JD, Grant RM, Kent CK. Detection of acute HIV infections. N Engl J Med 2005; 353:631-633.
38. Westreich DJ, Hudgens MG, Fiscus SA, Pilcher CD. Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests. J Clin Microbiol 2008; 46:1785-1792.
39. Kfutwah A, Lemee V, Ngono HV, et al. Field evaluation of the Abbott ARCHITECT HIV Ag/Ab Combo immunoassay. J Clin Virol 2013; 58 (Suppl 1):e70-e75.
40. Ly TD, Martin L, Daghfal D, et al. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J Clin Microbiol 2001; 39:3122-3128.
41. Ly TD, Ebel A, Faucher V, et al. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods 2007; 143:86-94.
42. Jurriaans S, Back NK, Wolthers KC. Ten years of HIV testing with fourth generation assays: the Amsterdam experience. J Clin Virol 2011; 52 (Suppl 1):S67-S69.
43. Jani IV, Meggi B, Mabunda N, et al. Accurate Early Infant HIV Diagnosis in Primary Health Clinics Using a Point-Of-Care Nucleic Acid Test. J Acquir Immune Defic Syndr 2014; 67:e1-e4.
44. Ritchie AV, Ushiro-Lumb I, Edemaga D, et al. SAMBA HIV semi-quantitative test, a new point-of-care viral load monitoring assay for resource-limited settings. J Clin Microbiol 2014; 52:3377-3383.
45. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of the determine(R) HIV-1/2 Ag/Ab combo test. J Infect Dis 2012; 205:528-534.
46. Jones CB, Kuldanek K, Muir D, et al. Clinical evaluation of the Determine HIV-1/2 Ag/Ab Combo test. J Infect Dis 2012; 206:1947-1949; author reply 9-50.
47. Taegtmeyer M, MacPherson P, Jones K, et al. Programmatic evaluation of a combined antigen and antibody test for rapid HIV diagnosis in a community and sexual health clinic screening programme. PLoS One 2011; 6:e28019.
48. Pavie J, Rachline A, Loze B, et al. Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One 2010; 5:e11581.
49. Conway DP, Holt M, McNulty A, et al. Multi-Centre Evaluation of the Determine HIV Combo Assay when Used for Point of Care Testing in a High Risk Clinic-Based Population. PLoS One 2014; 9:e94062.
50. Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol 2012; 54:180-184.
51. Pilcher CD, Louie B, Facente S, et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One 2013; 8:e80629.
52. Faraoni S, Rocchetti A, Gotta F, et al. Evaluation of a rapid antigen and antibody combination test in acute HIV infection. J Clin Virol 2013; 57:84-53.
53. Masciotra S, Luo W, Youngpairoj AS, et al. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol 2013; 58 (Suppl 1):e54-e58.
54. Brauer M, De Villiers JC, Mayaphi SH. Evaluation of the Determine fourth generation HIV rapid assay. J Virol Methods 2013; 189:180-183.
55. Pandori MW, Louie B, Pilcher C. Assessing the sensitivities of laboratory-based and point-of-care HIV antigen-antibody combination tests using a panel of specimens from recently and acutely infected individuals. HIV Diagn Conf 2010.
56. Laperche S, Leballais L, Ly TD, Plantier JC. Failures in the detection of HIV p24 antigen with the Determine HIV-1/2 Ag/Ab Combo rapid test. J Infect Dis 2012; 206:1946-1947.
57. Fox J, Dunn H, O'Shea S. Low rates of p24 antigen detection using a fourth-generation point of care HIV test. Sex Transm Infect 2011; 87:178-179.
58. Kilembe W, Keeling M, Karita E, et al. Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One 2012; 7:e37154.
59. Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods 2010; 168:218-222.
60. Food and Drug Administration. Approval letter - Alere Determine HIV-1/2Ag/Ab Combo 2013. 8 July 2014. http://www.fda.gov/biologicsbloodvac-cines/bloodbloodproducts/approvedproducts/%20premarketapprovalsp-mas/ucm364653.htm.
61. Hecht FM, Wellman R, Busch MP, et al. Identifying the early post-HIV antibody seroconversion period. J Infect Dis 2011; 204:526-533.
62. Schupbach J, Bisset LR, Gebhardt MD, et al. Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infect Dis 2012; 12:88.
63. Mor O, Mileguir F, Michaeli M, et al. Evaluation of the Bio-Rad Geenius HIV 1/2 Assay as an Alternative to the INNO-LIA HIV 1/2 Assay for Confirmation of HIV Infection. J Clin Microbiol 2014; 52:2677-2679.
64. Gay C, Dibben O, Anderson JA, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One 2011; 6:e19617.
65. Towler WI, James MM, Ray SC, et al. Analysis of HIV diversity using a highresolution melting assay. AIDS Res Hum Retroviruses 2010; 26:913-918.
66. Cousins MM, Laeyendecker O, Beauchamp G, et al. Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One 2011; 6:e27211.
67. Cousins MM, Swan D, Magaret CA, et al. Analysis of HIV using a high resolution melting (HRM) diversity assay: automation of HRM data analysis enhances the utility of the assay for analysis of HIV incidence. PLoS One 2012; 7:e51359.
68. Cousins MM, Konikoff J, Laeyendecker O 3rd, et al. HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. J Clin Microbiol 2014; 52:115-69.
69. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, et al. Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. J Infect Dis 2012; 206:756-764.
70. Shao W, Kearney MF, Boltz VF, et al. PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data. J Virol Methods 2014; 203:73-80.
71. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-10502.
72. Branson BM, Mermin J. Establishing the diagnosis of HIV infection: new tests and a new algorithm for the United States. J Clin Virol 2011; 52 (Suppl 1):S3-S4.
73. Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis 2012; 205:521-524.
74. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations; 27 June 2014.
75. Patel P, Klausner JD, Bacon OM, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 2006; 42:75-79.
76. Centers for Disease Control and Prevention. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm-United States, 2011-2013. MMWR Morbidity and mortality weekly report 2013; 62:489-77.
77. Goodhue T, Kazianis A, Werner BG, et al. 4th generation HIV screening in Massachusetts: a partnership between laboratory and program. J Clin Virol 2013; 58 (Suppl 1):e13-e18.
78. Emerson B, Plough K. Detection of acute HIV-1 infections utilizing NAAT technology in Dallas, Texas. J Clin Virol 2013; 58 (Suppl 1):e48-e53.
79. Christopoulos KA, Zetola NM, Klausner JD, et al. Leveraging a rapid, round-the-clock HIV testing system to screen for acute HIV infection in a large urban public medical center. J Acquir Immune Defic Syndr 2013; 62:e30-e38.
80. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection-United States, 2014. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control; 11 April 2014; 63:1-10.
81. Reniers G, Eaton J. Refusal bias in HIV prevalence estimates from nationally representative seroprevalence surveys. AIDS 2009; 23:621-629.
82. De Amici D, Klersy C, Ramajoli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Control Clin Trials 2000; 21:103-114.
83. Cui J, Becker NG. Estimating HIV incidence using dates of both HIV and AIDS diagnoses. Stat Med 2000; 19:1165-1177.
84. Becker NG, Lewis JJ, Li Z, McDonald A. Age-specific back-projection of HIV diagnosis data. Stat Med 2003; 22:2177-2190.
85. Wand H, Yan P, Wilson D, et al. Increasing HIV transmission through male homosexual and heterosexual contact in Australia: results from an extended back-projection approach. HIV Med 2010; 11:395-403.
86. Mallitt KA, Wilson DP, McDonald A, Wand H. Is back-projection methodology still relevant for estimating HIV incidence from national surveillance data? Open AIDS J 2012; 6:108-111.
87. Le Vu S, Pillonel J, Semaille C, et al. Principles and uses of HIV incidence estimation from recent infection testing: a review. Euro Surveill 2008; 13:18969.
88. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008; 13:18966.
89. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV ser-oincidence. J Acquir Immune Defic Syndr 2003; 33:625-634.
90. Parekh BS, Hu DJ, Vanichseni S, et al. Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV sero-conversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses 2001; 17:453-458.
91. Mastro TD, Kim AA, Hallett T, et al. Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. J HIV AIDS Surveill Epidemiol 2010; 2:1-14.
92. Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 2010; 24:2763-2771.
93. Karita E, Price M, Hunter E, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 2007; 21:403-408.
94. McDougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006; 22:945-952.
95. Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010; 26:61-71.
96. Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012; 7:e33328.
97. Konikoff J, Brookmeyer R, Longosz AF, et al. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS One 2013; 8:e82772.
98. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol 2013; 177:264-272.
99. Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr 2013; 63 (Suppl 2):S233-S239.
100. Eshleman SH, Hughes JP, Laeyendecker O, et al. Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis 2013; 207:223-231.
101. Laeyendecker O, Brookmeyer R, Cousins MM, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis 2013; 207:232-239.
102. Laeyendecker O, Brookmeyer R, Mullis CE, et al. Specificity of four laboratory approaches for cross-sectional HIV Incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses 2012; 28:1177-1183.
103. Laeyendecker O, Piwowar-Manning E, Fiamma A, et al. Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One 2013; 8:e68349.
104. Laeyendecker O, Latimore A, Eshleman SH, et al. The effect of sample handling on cross sectional HIV incidence testing results. PLoS One 2011; 6:e25899.
105. Welte A, McWalter TA, Laeyendecker O, Hallett TB. Using tests for recent infection to estimate incidence: problems and prospects for HIV. Euro Surveill 2010; 15:19589.
106. Kassanjee R, McWalter TA, Welte A. Short Communication: Defining optimality of a test for recent infection for HIV incidence surveillance. AIDS Res Hum Retroviruses 2014; 30:45-49.